trending Market Intelligence /marketintelligence/en/news-insights/trending/bxw6pp5x8g_1uahod6reow2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Strongbridge Biopharma closes private placement, enters credit facility

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Strongbridge Biopharma closes private placement, enters credit facility

Strongbridge Biopharma PLC completed its private placement of ordinary shares and warrants to raise $35 million in gross proceeds.

The company also entered into a senior credit facility with Oxford Finance LLC and Horizon Technology Finance. The facility consists of $20 million borrowed initially with access to two additional tranches of $10 million, which would become available subject to the achievement of certain specified milestones.

The credit facility matures after 48 months, provides for interest-only payments for the first 18 months followed by an amortization period of 30 months, provides for a final payment fee equal to 8% of the amount borrowed and bears interest at a rate equal to the sum of 8.22% plus the greater of 0.53% or the 30-day U.S. LIBOR rate.

In case Strongbridge reaches its milestones and borrows the final $10 million tranche, the interest-only period would be extended by an additional six months and the amortization period would be 24 months.

Strongbridge has granted a security interest in substantially all of its existing and after-acquired assets, including intellectual property. It also issued 10-year warrants to the lenders to purchase an aggregate of 428,571 ordinary shares priced at $2.45 per share.